Company News

Share this article:
Eli Lilly is trimming its osteoporosis, diabetes and neurosciences sales forces by a total of 191 jobs as part of a restructuring plan announced in September, Indianapolis Business Journal reports. The company intends to lay off 5,500 by 2011 in an effort to soften the blow when Zyprexa, which has $4.7 billion in global sales, goes off patent the same year.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.